Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death

BMC Cancer

Pier Vitale Nuzzo¹  Alessandra Rubagotti¹  Linda Zinoli¹  Francesco Ricci¹  Sandra Salvi²  Simona Boccardo²  Francesco Boccardo¹ 

[1] University of Genoa, Department of Internal Medicine, School of Medicine, Genoa, Italy

[2] IRCCS San Martino University Hospital – IST National Cancer Research Institute, Pathology Unit, Genoa, Italy

关键词: Biomarkers;    Prognosis;    Extracellular matrix proteins;    Prostatic neoplasms;    Human;    POSTN protein;   

Others  :  1079992
DOI  :  10.1186/1471-2407-12-625

 received in 2012-07-05, accepted in 2012-12-17,  发布年份 2012

【 摘 要 】

Background

The purpose of the present study was to evaluate the prognostic value of POSTN expression following prostatectomy.

Methods

Periostin (POSTN) expression in prostate cancer (PCa) and in normal specimens was evaluated in 90 patients by an immuno-reactive score(IRS) based on the intensity of immunostaining and on the quantity of stained cells. The t-test was applied to compare IRS values in cancer specimens to values in normal specimens. Pearson’s test was used to correlate POSTN expression to clinical pathologic features. PSA progression-free and survival curves were constructed by the Kaplan–Meier method and compared using the log-rank test. Multi-parametric models were constructed according to the Cox technique adding all the covariates predicting for either PSA progression or death into the models after univariate analysis.

Results

Both stromal and epithelial POSTN expression were significantly increased in tumor tissues. In particular, we found stromal expression to be significantly higher than epithelial expression as compared to normal tissues (p<0.000 and p=0.001).A significant correlation between POSTN epithelial expression and extra-prostatic extension was found (p=0.03). While high stromal expression was significantly associated with shorter survival (p=0.008), a low epithelial score significantly correlated with shorter PSA-free survival (p=0.04), suggesting that POSTN plays an apparently opposing biological role depending on its compartmentalization.Regardless of the mechanism that is involved, patients showing both high stromal and low epithelial expression made up a subgroup with a very bleak prognosis.

Conclusions

Although requiring further validation through larger studies, our findings show that POSTN might represent a novel prognostic marker for PCa.

【 授权许可】

   
2012 Nuzzo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
• [2]Bostwick DG, Grignon DJ, Hammond ME, et al.: Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124(7):995-1000.
• [3]Humphrey PA, Vollmer RT: Percentage of carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 1997, 10:326-33.
• [4]Tefilli MV, Gheiler EL, Tiguert R, et al.: Should Gleason score 7 prostate cancer be considered a unique grade category? Urology 1999, 53:372-377.
• [5]Montironi R, Mazzuccheli R, Scarpelli M, Lopez-Beltran A, Fellegara G, Algaba F: Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int 2005, 95(8):1146-52.
• [6]Boccardo F, Rubagotti A, Carmignani G, Romagnoli A, Nicolò G, Barboro P, Parodi S, Patrone E, Balbi C: Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic value in clinically localized prostate cancer. Prostate 2003, 55:259-64.
• [7]Ricci F, Rubagotti A, Zinoli L, Mangerii R, Nuzzo PV, Carmignani G, Simonato A, Barboro P, Balbi C, Boccardo F: Prognostic value of nuclear matrix protein expression in localized prostate cancer. J Cancer Res Clin Oncol 2012, 138(8):1379-84.
• [8]Ruan K, Bao S, Ouyang G: The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci 2009, 66(14):2219-30.
• [9]Oshima A, Tanabe H, Yan T, Lowe GN, Glackin CA, Kudo A: A novel mechanism for the regulation of osteoblast differentiation: transcription of periostin, a member of the fasciclin I family, is regulated by the bHLH transcription factor, twist. J Cell Biochem 2002, 86(4):792-804.
• [10]Shimazaki M, Nakamura K, Kii I, Kashima T, Amizuka N, Li M, Saito M, Fukuda K, Nishiyama T, Kitajima S, et al.: Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med 2008, 205(2):295-303.
• [11]Nakazawa T, Nakajima A, Seki N, Okawa A, Kato M, Moriya H, Amizuka N, Einhorn TA, Yamazaki M: Gene expression of periostin in the early stage of fracture healing detected by cDNA microarray analysis. J Orthop Res 2004, 22(3):520-525.
• [12]Li P, Oparil S, Feng W, Chen YF: Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells. J Appl Physiol 2004, 97(4):1550-1558. discussion 1549
• [13]Morra L, Moch H: Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Arch 2011, 459(5):465-75.
• [14]Kim CJ, Yoshioka N, Tambe Y, Kushima R, Okada Y, Inoue H: Periostin is down-regulated in high grade human bladder cancers and suppresses in vitro cell invasiveness and in vivo metastasis of cancer cells. Int J Cancer 2005, 117(1):51-8.
• [15]Tsunoda T, Furusato B, Takashima Y, Ravulapalli S, Dobi A, Srivastava S, McLeod DG, Sesterhenn IA, Ornstein DK, Shirasawa S: The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma. Prostate 2009, 69(13):1398-403.
• [16]Tischler V, Fritzsche FR, Wild PJ, Stephan C, Seifert HH, Riener MO, Hermanns T, Mortezavi A, Gerhardt J, Schraml P, Jung K, Moch H, Soltermann A, Kristiansen G: Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer 2010, 10:273. BioMed Central Full Text
• [17]Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
• [18]Peto R, Pike MC, Armitage P, et al.: Design and analysis of randomised clinical trials requiring prolonged observation of each patient: I. Introduction and design. Br J Cancer 1976, 34:585-612. Analysis and examples. Br J Cancer 1977;35:1–39
• [19]Cox DR: Regression models and life-tables. J R Stat Soc Ser B 1972, 34:187-220.